Clinical trial results:
A 16-Week, Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily PF-06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise

Summary

EudraCT number	2019-000218-12
Trial protocol	SK HU PL BG
Global end of trial date	07 July 2021

Results information

Result version number	v1 (current)
This version publication date	18 June 2022
First version publication date	18 June 2022

Trial information

Trial identification

Sponsor protocol code	C3421005

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03985293
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 July 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 July 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the effect of multiple dose levels of danuglipron (PF-06882961) versus placebo on glycated hemoglobin (HbA1c) in subjects with type 2 diabetes mellitus (T2DM) on stable doses of metformin and/or diet and exercise.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 July 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 6
Country: Number of subjects enrolled	Canada: 29
Country: Number of subjects enrolled	Hungary: 72
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 10
Country: Number of subjects enrolled	Poland: 36
Country: Number of subjects enrolled	Slovakia: 36
Country: Number of subjects enrolled	Taiwan: 14
Country: Number of subjects enrolled	United States: 208
Worldwide total number of subjects	411
EEA total number of subjects	150

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	291
From 65 to 84 years	120
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 859 subjects were screened in the study, of which, 412 subjects were randomized, and 411 subjects were treated with PF-06882961 (Danuglipron)/placebo; 1 subject randomized to the PF-06882961 120 mg BID group was not treated.

Period 1

Period 1 title	DOUBLE-BLIND TREATMENT
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm title	PF-06882961 2.5mg BID

Arm description:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm title	PF-06882961 10mg BID

Arm description:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.

Arm type	Experimental

Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm title	PF-06882961 40mg BID

Arm description:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm title	PF-06882961 80mg BID

Arm description:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm title	PF-06882961 120mg BID

Arm description:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Number of subjects in period 1	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID
Started	66	68	68
Completed	57	54	63
Not completed	9	14	5
Consent withdrawn by subject	-	4	2
Adverse event, non-fatal	5	2	3
Unspecified	1	2	-
Lost to follow-up	1	3	-
No Longer Meets Eligibility Criteria	1	1	-
Protocol deviation	1	2	-

Number of subjects in period 1	PF-06882961 40mg BID	PF-06882961 80mg BID	PF-06882961 120mg BID
Started	71	67	71
Completed	57	47	38
Not completed	14	20	33
Consent withdrawn by subject	-	1	7
Adverse event, non-fatal	8	15	24
Unspecified	2	1	-
Lost to follow-up	3	3	1
No Longer Meets Eligibility Criteria	1	-	-
Protocol deviation	-	-	1

Period 2

Period 2 title	FOLLOW-UP
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm title	PF-06882961 2.5mg BID

Arm description:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm title	PF-06882961 10mg BID

Arm description:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Arm title	PF-06882961 40mg BID

Arm description:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm title	PF-06882961 80mg BID

Arm description:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm title	PF-06882961 120mg BID

Arm description:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Arm type	Experimental
Investigational medicinal product name	danuglipron
Investigational medicinal product code	PF-06882961
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Number of subjects in period 2	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID
Started	57	54	63
Completed	57	54	62
Not completed	0	0	1
Lost to follow-up	-	-	1

Number of subjects in period 2	PF-06882961 40mg BID	PF-06882961 80mg BID	PF-06882961 120mg BID
Started	57	47	38
Completed	57	47	38
Not completed	0	0	0
Lost to follow-up	-	-	-

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.	
Reporting group title	PF-06882961 2.5mg BID
Reporting group description:	
PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.	
Reporting group title	PF-06882961 10mg BID
Reporting group description:	
PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.	
Reporting group title	PF-06882961 40mg BID
Reporting group description:	
PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.	
Reporting group title	PF-06882961 80mg BID
Reporting group description:	
PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.	
Reporting group title	PF-06882961 120mg BID
Reporting group description:	
PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.	

Reporting group values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID
Number of subjects	66	68	68
Age Categorical Units: Subjects			
Adults (18-64 years)	50	47	48
Adults (65-84 years)	16	21	20
Age Continuous Units: Years			
arithmetic mean	57.9	58.9	58.1
standard deviation	± 10.27	± 9.30	± 9.43
Sex: Female, Male Units: Subjects			
Male	33	38	35
Female	33	30	33
Race/Ethnicity, Customized Units: Subjects			
White	57	57	53
Black or African American	2	4	10
Asian	5	7	4
Native Hawaiian or Other Pacific Islander	1	0	0
Not reported	1	0	1
Ethnicity (NIH/OMB)			

Units: Subjects			
Hispanic or Latino	24	22	17
Not Hispanic or Latino	42	46	50
Unknown or Not Reported	0	0	1

Reporting group values	PF-06882961 40mg BID	PF-06882961 80mg BID	PF-06882961 120mg BID
Number of subjects	71	67	71
Age Categorical			
Units: Subjects			
Adults (18-64 years)	47	47	52
Adults (65-84 years)	24	20	19
Age Continuous			
Units: Years			
arithmetic mean	59.6	58.4	58.8
standard deviation	± 8.58	± 9.18	± 9.43
Sex: Female, Male			
Units: Subjects			
Male	34	35	34
Female	37	32	37
Race/Ethnicity, Customized			
Units: Subjects			
White	58	59	59
Black or African American	6	1	4
Asian	6	6	7
Native Hawaiian or Other Pacific Islander	0	0	1
Not reported	1	1	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	24	23	18
Not Hispanic or Latino	47	44	52
Unknown or Not Reported	0	0	1

Reporting group values	Total		
Number of subjects	411		
Age Categorical			
Units: Subjects			
Adults (18-64 years)	291		
Adults (65-84 years)	120		
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Subjects			
Male	209		
Female	202		
Race/Ethnicity, Customized			
Units: Subjects			
White	343		
Black or African American	27		

Asian	35		
Native Hawaiian or Other Pacific Islander	2		
Not reported	4		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	128		
Not Hispanic or Latino	281		
Unknown or Not Reported	2		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.	
Reporting group title	PF-06882961 2.5mg BID
Reporting group description:	
PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.	
Reporting group title	PF-06882961 10mg BID
Reporting group description:	
PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up.	
Reporting group title	PF-06882961 40mg BID
Reporting group description:	
PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.	
Reporting group title	PF-06882961 80mg BID
Reporting group description:	
PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.	
Reporting group title	PF-06882961 120mg BID
Reporting group description:	
PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks, followed by an approximate 4-week follow-up. Titration was implemented.	
Reporting group title	Placebo
Reporting group description:	
Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.	
Reporting group title	PF-06882961 2.5mg BID
Reporting group description:	
PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.	
Reporting group title	PF-06882961 10mg BID
Reporting group description:	
PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.	
Reporting group title	PF-06882961 40mg BID
Reporting group description:	
PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.	
Reporting group title	PF-06882961 80mg BID
Reporting group description:	
PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.	
Reporting group title	PF-06882961 120mg BID
Reporting group description:	
PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.	

Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16	
End point title	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Primary

End point timeframe:

Baseline, Week 16

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	52	61	55
Units: Percent				
least squares mean (confidence interval 90%)	-0.02 (-0.22 to 0.19)	-0.49 (-0.70 to -0.28)	-0.91 (-1.11 to -0.72)	-1.03 (-1.23 to -0.83)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	38		
Units: Percent				
least squares mean (confidence interval 90%)	-0.96 (-1.18 to -0.74)	-1.18 (-1.41 to -0.95)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0071
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.47
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.76
upper limit	-0.18

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.18
upper limit	-0.62

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-1.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.3
upper limit	-0.73

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.94

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.24
upper limit	-0.65

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-1.16
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.47
upper limit	-0.86

Secondary: Percentage of Subjects Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels

End point title	Percentage of Subjects Achieving Less Than (<) 7% Glycated Hemoglobin (HbA1c) Levels

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	52	61	55
Units: Percentage of Subjects				
number (not applicable)	7.7	30.8	54.1	58.2

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	38		
Units: Percentage of Subjects				
number (not applicable)	65.2	60.5		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	5.11
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.84
upper limit	14.18

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	16.85
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.18
upper limit	45.93

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	18.79

Confidence interval	
level	90 %
sides	2-sided
lower limit	7.03
upper limit	50.21

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	23.97
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.66
upper limit	66.39

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	24.46
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.72
upper limit	68.57

Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2

End point title	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 2

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	64	67	67
Units: Percent				
least squares mean (confidence interval 90%)	-0.09 (-0.17 to -0.01)	-0.18 (-0.26 to -0.09)	-0.31 (-0.39 to -0.23)	-0.29 (-0.37 to -0.21)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	69		
Units: Percent				
least squares mean (confidence interval 90%)	-0.33 (-0.41 to -0.24)	-0.35 (-0.43 to -0.28)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1578
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.09
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.19
upper limit	0.01

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.22

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.32
upper limit	-0.12

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.3
upper limit	-0.1

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.24
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.34
upper limit	-0.14

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	134
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.26
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.36
upper limit	-0.16

Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4

End point title	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 4

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 4

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	68	63
Units: Percent				
least squares mean (confidence interval 90%)	-0.08 (-0.19 to 0.04)	-0.38 (-0.50 to -0.26)	-0.51 (-0.62 to -0.39)	-0.63 (-0.74 to -0.52)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	54	60		
Units: Percent				
least squares mean (confidence interval 90%)	-0.58 (-0.70 to -0.46)	-0.64 (-0.75 to -0.53)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	118
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.46
upper limit	-0.15

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.43
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.58
upper limit	-0.28

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	123
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.55
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	-0.4

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.66
upper limit	-0.35

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	120
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.56
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.71
upper limit	-0.41

Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6

End point title	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 6

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	55	66	59
Units: Percent				
least squares mean (confidence interval 90%)	-0.07 (-0.21 to 0.07)	-0.47 (-0.61 to -0.34)	-0.71 (-0.84 to -0.57)	-0.84 (-0.97 to -0.71)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	52		
Units: Percent				
least squares mean (confidence interval 90%)	-0.79 (-0.93 to -0.65)	-0.84 (-0.98 to -0.71)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.59
upper limit	-0.22

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	126
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.64

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.81
upper limit	-0.46

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.77
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.95
upper limit	-0.59

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	111
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.72
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.91
upper limit	-0.53

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	112
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.77
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.95
upper limit	-0.59

Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8

End point title	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 8

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 8

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	51	66	58
Units: Percent				
least squares mean (confidence interval 90%)	-0.13 (-0.29 to 0.03)	-0.50 (-0.66 to -0.34)	-0.78 (-0.93 to -0.62)	-0.97 (-1.13 to -0.82)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	42		
Units: Percent				
least squares mean (confidence interval 90%)	-0.92 (-1.09 to -0.76)	-1.02 (-1.18 to -0.86)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0054
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.37
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.59
upper limit	-0.15

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.65
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.86
upper limit	-0.44

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.84
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.06
upper limit	-0.63

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.02
upper limit	-0.57

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.89
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.11
upper limit	-0.67

Secondary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12

End point title	Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12

End point description:

HbA1c can be used as a diagnostic test for diabetes. The target HbA1c level for people with diabetes is usually less than 7%. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	55	53	63	58
Units: Percent				
least squares mean (confidence interval 90%)	-0.09 (-0.28 to 0.10)	-0.53 (-0.72 to -0.34)	-0.88 (-1.06 to -0.70)	-1.06 (-1.25 to -0.88)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	38		
Units: Percent				
least squares mean (confidence interval 90%)	-0.91 (-1.12 to -0.71)	-1.11 (-1.32 to -0.91)		

Statistical analyses

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	118
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.79
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.05
upper limit	-0.54

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	108
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0061
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.44

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.71
upper limit	-0.18

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.83
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.1
upper limit	-0.56

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.98
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.24
upper limit	-0.72

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-1.03
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.3
upper limit	-0.75

Secondary: Change From Baseline in Fasting Plasma Glucose at Week 2

End point title	Change From Baseline in Fasting Plasma Glucose at Week 2

End point description:

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 milligram per deciliter (mg/dL) to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	64	67	68
Units: mg/dL				
least squares mean (confidence interval 90%)	-5.58 (-12.66 to 1.49)	-22.72 (-29.78 to -15.65)	-21.96 (-28.91 to -15.01)	-27.79 (-34.60 to -20.98)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	68		
Units: mg/dL				
least squares mean (confidence interval 90%)	-24.18 (-31.28 to -17.08)	-30.92 (-37.66 to -24.17)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID

Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0014
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-17.13
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.94
upper limit	-8.33

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	132
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0021
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-16.38
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.08
upper limit	-7.67

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-22.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-30.88
upper limit	-13.53

Statistical analysis title	PF-06882961 80mg BID versus Placebo

Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-18.59
Confidence interval	
level	90 %
sides	2-sided
lower limit	-27.43
upper limit	-9.76

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-25.33
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34
upper limit	-16.67

Secondary: Change From Baseline in Fasting Plasma Glucose at Week 4

End point title	Change From Baseline in Fasting Plasma Glucose at Week 4

End point description:

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 4

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	68	62
Units: mg/dL				
least squares mean (confidence interval 90%)	-5.98 (-13.62 to 1.66)	-17.77 (-25.46 to -10.09)	-24.66 (-31.98 to -17.35)	-33.42 (-40.83 to -26.00)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	55	60		
Units: mg/dL				
least squares mean (confidence interval 90%)	-33.34 (-41.25 to -25.44)	-34.06 (-41.52 to -26.00)		

Statistical analyses

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	118
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0468
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-11.79
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21.55
upper limit	-2.04

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0012
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-18.68

Confidence interval	
level	90 %
sides	2-sided
lower limit	-28.12
upper limit	-9.25

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-27.44
Confidence interval	
level	90 %
sides	2-sided
lower limit	-37.03
upper limit	-17.85

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-27.36
Confidence interval	
level	90 %
sides	2-sided
lower limit	-37.22
upper limit	-17.51

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	120
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-28.09
Confidence interval	
level	90 %
sides	2-sided
lower limit	-37.72
upper limit	-18.45

Secondary: Change From Baseline in Fasting Plasma Glucose at Week 6

End point title	Change From Baseline in Fasting Plasma Glucose at Week 6

End point description:

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	55	66	60
Units: mg/dL				
least squares mean (confidence interval 90%)	-0.88 (-8.62 to 6.86)	-16.78 (-24.67 to -8.89)	-26.41 (-33.88 to -18.94)	-30.89 (-38.47 to -23.30)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	53		
Units: mg/dL				
least squares mean (confidence interval 90%)	-28.36 (-36.51 to -20.21)	-32.65 (-40.44 to -24.87)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID

Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0091
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-15.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.9
upper limit	-5.9

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	126
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-25.53
Confidence interval	
level	90 %
sides	2-sided
lower limit	-35.18
upper limit	-15.89

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	120
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-30.01
Confidence interval	
level	90 %
sides	2-sided
lower limit	-39.8
upper limit	-20.21

Statistical analysis title	PF-06882961 80mg BID versus Placebo

Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	111
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-27.48
Confidence interval	
level	90 %
sides	2-sided
lower limit	-37.63
upper limit	-17.33

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-31.77
Confidence interval	
level	90 %
sides	2-sided
lower limit	-41.77
upper limit	-21.78

Secondary: Change From Baseline in Fasting Plasma Glucose at Week 8

End point title	Change From Baseline in Fasting Plasma Glucose at Week 8

End point description:

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 8

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	57	53	64	58
Units: mg/dL				
least squares mean (confidence interval 90%)	-9.10 (-16.80 to -1.41)	-12.73 (-20.53 to -4.93)	-26.23 (-33.57 to -18.89)	-29.74 (-37.26 to -22.23)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	42		
Units: mg/dL				
least squares mean (confidence interval 90%)	-33.22 (-41.36 to -25.09)	-34.31 (-42.46 to -26.16)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5449
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-3.63
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.51
upper limit	6.25

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0031
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-17.12

Confidence interval	
level	90 %
sides	2-sided
lower limit	-26.62
upper limit	-7.63

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-20.64
Confidence interval	
level	90 %
sides	2-sided
lower limit	-30.31
upper limit	-10.96

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-24.12
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.2
upper limit	-14.04

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-25.21
Confidence interval	
level	90 %
sides	2-sided
lower limit	-35.44
upper limit	-14.97

Secondary: Change From Baseline in Fasting Plasma Glucose at Week 12

End point title	Change From Baseline in Fasting Plasma Glucose at Week 12

End point description:

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	55	53	63	58
Units: mg/dL				
least squares mean (confidence interval 90%)	1.21 (-7.93 to 10.35)	-6.49 (-15.70 to 2.73)	-22.56 (-31.17 to -13.95)	-32.01 (-40.89 to -23.14)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	37		
Units: mg/dL				
least squares mean (confidence interval 90%)	-30.45 (-40.26 to -20.64)	-32.38 (-42.83 to -21.94)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID

Number of subjects included in analysis	108
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.294
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-7.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.78
upper limit	4.38

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	118
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-23.77
Confidence interval	
level	90 %
sides	2-sided
lower limit	-35.37
upper limit	-12.17

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-33.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-45.05
upper limit	-21.4

Statistical analysis title	PF-06882961 80mg BID versus Placebo

Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-31.66
Confidence interval	
level	90 %
sides	2-sided
lower limit	-44.14
upper limit	-19.19

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-33.59
Confidence interval	
level	90 %
sides	2-sided
lower limit	-46.67
upper limit	-20.51

Secondary: Change From Baseline in Fasting Plasma Glucose at Week 16

End point title	Change From Baseline in Fasting Plasma Glucose at Week 16

End point description:

The fasting plasma glucose test measures the levels of glucose (sugar) in the blood, with a normal range of 70 mg/dL to 99 mg/dL. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	52	61	56
Units: mg/dL				
least squares mean (confidence interval 90%)	1.31 (-7.58 to 10.20)	-12.81 (-21.71 to -3.91)	-24.53 (-32.88 to -16.18)	-30.47 (-39.06 to -21.87)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	45	38		
Units: mg/dL				
least squares mean (confidence interval 90%)	-25.71 (-35.15 to -16.26)	-31.93 (-41.73 to -22.13)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0464
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-14.12
Confidence interval	
level	90 %
sides	2-sided
lower limit	-25.77
upper limit	-2.47

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-25.84

Confidence interval	
level	90 %
sides	2-sided
lower limit	-37.05
upper limit	-14.62

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	108
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-31.78
Confidence interval	
level	90 %
sides	2-sided
lower limit	-43.2
upper limit	-20.35

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-27.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	-39.03
upper limit	-15.01

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-33.24
Confidence interval	
level	90 %
sides	2-sided
lower limit	-45.63
upper limit	-20.84

Secondary: Change From Baseline in Body Weight at Week 2

End point title	Change From Baseline in Body Weight at Week 2

End point description:

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	64	68	68
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.15 (-0.47 to 0.17)	-0.09 (-0.41 to 0.23)	-0.12 (-0.44 to 0.19)	-0.23 (-0.54 to 0.08)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	69		
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.57 (-0.89 to -0.24)	-0.54 (-0.85 to -0.24)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8011
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.06
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.33
upper limit	0.44

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9149
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.02
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.35
upper limit	0.4

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7216
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.46
upper limit	0.3

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	128
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0758
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.42
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.8
upper limit	-0.03

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	134
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.086
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.77
upper limit	-0.02

Secondary: Change From Baseline in Body Weight at Week 4	
End point title	Change From Baseline in Body Weight at Week 4
End point description:	
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.	
End point type	Secondary
End point timeframe:	
Baseline, Week 4	

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	61	58	68	63
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.25 (-0.64 to 0.15)	-0.33 (-0.72 to 0.07)	-0.08 (-0.46 to 0.30)	-0.77 (-1.15 to -0.39)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	55	61		
Units: Kilogram				
least squares mean (confidence interval 90%)	-1.05 (-1.45 to -0.64)	-1.33 (-1.71 to -0.95)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	119
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7898
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.08
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.59
upper limit	0.42

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5829
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.16

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.33
upper limit	0.66

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	124
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0827
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.52
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.02
upper limit	-0.03

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	116
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0101
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.31
upper limit	-0.29

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-1.09
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.59
upper limit	-0.59

Secondary: Change From Baseline in Body Weight at Week 6

End point title	Change From Baseline in Body Weight at Week 6

End point description:

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	55	66	60
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.09 (-0.57 to 0.40)	-0.19 (-0.68 to 0.31)	-0.32 (-0.78 to 0.15)	-0.83 (-1.31 to -0.36)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	53		
Units: Kilogram				
least squares mean (confidence interval 90%)	-1.69 (-2.20 to -1.19)	-2.34 (-2.83 to -1.85)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7985
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.75
upper limit	0.55

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	126
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5484
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.86
upper limit	0.4

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	120
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0541
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.75
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.38
upper limit	-0.11

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	111
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-1.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.26
upper limit	-0.95

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-2.25
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.9
upper limit	-1.6

Secondary: Change From Baseline in Body Weight at Week 8

End point title	Change From Baseline in Body Weight at Week 8

End point description:

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 8

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	57	54	66	58
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.36 (-0.89 to 0.16)	-0.05 (-0.59 to 0.49)	-0.27 (-0.78 to 0.23)	-1.09 (-1.60 to -0.57)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	42		
Units: Kilogram				
least squares mean (confidence interval 90%)	-1.97 (-2.52 to -1.42)	-3.31 (-3.85 to -2.77)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	111
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4692
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.31
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.4
upper limit	1.03

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	123
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8274
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.09

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.6
upper limit	0.78

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0887
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.72
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.42
upper limit	-0.02

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-1.61
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.33
upper limit	-0.88

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-2.95
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.67
upper limit	-2.22

Secondary: Change From Baseline in Body Weight at Week 12

End point title	Change From Baseline in Body Weight at Week 12

End point description:

Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	55	53	63	58
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.24 (-0.85 to 0.38)	-0.09 (-0.72 to 0.53)	-0.00 (-0.59 to 0.58)	-1.05 (-1.65 to -0.44)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	38		
Units: Kilogram				
least squares mean (confidence interval 90%)	-2.52 (-3.17 to -1.87)	-3.81 (-4.46 to -3.16)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	108
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7758
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.15
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.7
upper limit	0.99

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	118
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6367
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.58
upper limit	1.05

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	113
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1082
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.81
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.63
upper limit	0.02

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-2.28
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.14
upper limit	-1.42

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-3.57
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.44
upper limit	-2.7

Secondary: Change From Baseline in Body Weight at Week 16

End point title	Change From Baseline in Body Weight at Week 16
End point description:	
Weight was recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.	
End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	52	53	62	57
Units: Kilogram				
least squares mean (confidence interval 90%)	-0.43 (-1.12 to 0.25)	0.02 (-0.68 to 0.72)	-0.06 (-0.71 to 0.60)	-1.16 (-1.84 to -0.49)

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	38		
Units: Kilogram				
least squares mean (confidence interval 90%)	-2.48 (-3.20 to -1.75)	-4.60 (-5.34 to -3.86)		

Statistical analyses

Statistical analysis title	PF-06882961 2.5mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 2.5mg BID
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4325
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.45
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.5
upper limit	1.41

Statistical analysis title	PF-06882961 10mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 10mg BID
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4978
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	0.38

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.54
upper limit	1.3

Statistical analysis title	PF-06882961 40mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 40mg BID
Number of subjects included in analysis	109
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.197
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-0.73
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.66
upper limit	0.2

Statistical analysis title	PF-06882961 80mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 80mg BID
Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-2.04
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.01
upper limit	-1.07

Statistical analysis title	PF-06882961 120mg BID versus Placebo
Comparison groups	Placebo v PF-06882961 120mg BID

Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS Mean
Point estimate	-4.17
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.15
upper limit	-3.18

Secondary: Number of Subjects With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])

End point title	Number of Subjects With Treatment Emergent Adverse Events (Adverse Events [AEs] and Serious Adverse Events [SAEs])

End point description:

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent. Safety analysis set included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment.

End point type	Secondary

End point timeframe:

Baseline up to Week 21

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	66	68	68	71
Units: Subjects				
Number of Subjects With Treatment Emergent AEs	32	32	31	42
Number of Subjects With Treatment Emergent SAEs	1	1	2	6

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	67	71		
Units: Subjects				
Number of Subjects With Treatment Emergent AEs	43	44		

Number of Subjects With Treatment Emergent SAEs	2	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality

End point title	Number of Subjects With Treatment Emergent Clinical Laboratory Abnormalities Without Regard to Baseline Abnormality

End point description:

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, PT/INR, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin); lipid panel (low density lipoprotein cholesterol, high density lipoprotein cholesterol). Overall number of subjects analyzed included all subjects randomly assigned to study treatment and who took at least 1 dose of study treatment and had at least 1 measurement available.

End point type	Secondary

End point timeframe:

Baseline Through Week 21

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	68	68	71
Units: Subjects				
Number of Subjects With Laboratory Abnormalities	60	57	57	57

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	67	71		
Units: Subjects				
Number of Subjects With Laboratory Abnormalities	60	64		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Vital Signs Abnormalities

End point title	Number of Subjects With Treatment Emergent Vital Signs Abnormalities

End point description:

Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) <50 mmHg; 3) supine pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP >= 20 mmHg. Overall number of subjects analyzed included all subjects randomly assigned to study treatment, took at least 1 dose of study treatment and had at least 1 measurement available.

End point type	Secondary

End point timeframe:

Baseline through Week 21

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	68	68	71
Units: Subjects				
Supine SBP <90 mmHg	0	0	0	0
Supine SBP increase >=30 mmHg	3	4	3	3
Supine SBP decrease >=30 mmHg	4	4	3	5
Supine DBP <50 mmHg	1	0	0	1
Supine DBP increase >=20 mmHg	1	1	2	3
Supine DBP decrease >=20 mmHg	3	4	1	3
Supine pulse rate <40 bpm	0	0	0	0
Supine pulse rate >120 bpm	0	0	0	0

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	67	71		
Units: Subjects				
Supine SBP <90 mmHg	0	0		
Supine SBP increase >=30 mmHg	0	5		
Supine SBP decrease >=30 mmHg	5	0		
Supine DBP <50 mmHg	0	1		
Supine DBP increase >=20 mmHg	3	3		
Supine DBP decrease >=20 mmHg	2	1		
Supine pulse rate <40 bpm	0	0		
Supine pulse rate >120 bpm	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent ECG Abnormalities

End point title	Number of Subjects With Treatment Emergent ECG Abnormalities

End point description:

ECG categorical abnormality criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (>=) 300 millisecond (msec), b) >=25% increase when baseline is > 200 msec or >=50% increase when baseline is less than or equal to (<=) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) >=140 msec, b) >=50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) >450 msec and <=480 msec, b) >480 msec and <=500 msec, c) >500 msec, d) >30 msec and <=60 msec increase from baseline, e) >60 msec increase from baseline. Overall number of subjects analyzed included all subjects randomly assigned to study treatment, took at least 1 dose of study treatment and had at least 1 measurement available.

End point type	Secondary

End point timeframe:

Baseline Through Week 21

End point values	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID	PF-06882961 40mg BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	65	68	68	71
Units: Subjects				
PR interval ≥300 msec	0	0	0	0
%Change in PR interval ≥25/50%	3	0	0	0
QRS interval ≥140 msec	1	1	0	0
%Change in QRS interval ≥50%	1	1	0	0
QTcF interval >450 and ≤480 msec	2	3	2	1
QTcF interval >480 and ≤500 msec	0	0	0	0
QTcF interval >500 msec	0	0	0	0
Change in QTcF interval >30 and ≤60 msec	2	3	2	6
Change in QTcF interval >60 msec	0	0	1	1

End point values	PF-06882961 80mg BID	PF-06882961 120mg BID		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	67	71		
Units: Subjects				
PR interval ≥300 msec	0	1		
%Change in PR interval ≥25/50%	1	0		
QRS interval ≥140 msec	0	0		
%Change in QRS interval ≥50%	0	0		
QTcF interval >450 and ≤480 msec	3	4		
QTcF interval >480 and ≤500 msec	0	1		
QTcF interval >500 msec	0	0		
Change in QTcF interval >30 and ≤60 msec	3	6		

Change in QTcF interval >60 msec	0	3		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 21

Adverse event reporting additional description:

For the number of adverse events, if the same subject in a given treatment had more than 1 occurrence in the same preferred term event category, the preferred term event for the subject was counted once, and only the most severe occurrence was counted.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	24.0

Reporting groups

Reporting group title	Placebo

Reporting group description:

Placebo matched to PF-06882961 was administered orally twice daily (BID) with food for a total of 16 weeks.

Reporting group title	PF-06882961 2.5mg BID

Reporting group description:

PF-06882961 2.5 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Reporting group title	PF-06882961 10mg BID

Reporting group description:

PF-06882961 10 mg was administered orally twice daily (BID) with food for a total of 16 weeks.

Reporting group title	PF-06882961 40mg BID

Reporting group description:

PF-06882961 40 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Reporting group title	PF-06882961 80mg BID

Reporting group description:

PF-06882961 80 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Reporting group title	PF-06882961 120mg BID

Reporting group description:

PF-06882961 120 mg was administered orally twice daily (BID) with food for a total of 16 weeks. Titration was implemented.

Serious adverse events	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 66 (1.52%)	1 / 68 (1.47%)	2 / 68 (2.94%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	1	0
Investigations			
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	1 / 66 (1.52%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 66 (0.00%)	1 / 68 (1.47%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			

subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Multiple sclerosis			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	1 / 68 (1.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	1 / 68 (1.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19 pneumonia			
subjects affected / exposed	0 / 66 (0.00%)	1 / 68 (1.47%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia			

subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-06882961 40mg BID	PF-06882961 80mg BID	PF-06882961 120mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 71 (8.45%)	2 / 67 (2.99%)	1 / 71 (1.41%)
number of deaths (all causes)	2	0	0
number of deaths resulting from adverse events	2	0	0
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SARS-CoV-2 test positive			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma			
subjects affected / exposed	0 / 71 (0.00%)	0 / 67 (0.00%)	1 / 71 (1.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 71 (0.00%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			

subjects affected / exposed	0 / 71 (0.00%)	1 / 67 (1.49%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 71 (0.00%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Multiple sclerosis			
subjects affected / exposed	0 / 71 (0.00%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 71 (0.00%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 71 (0.00%)	1 / 67 (1.49%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			

subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
COVID-19 pneumonia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 71 (1.41%)	0 / 67 (0.00%)	0 / 71 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	PF-06882961 2.5mg BID	PF-06882961 10mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 66 (22.73%)	21 / 68 (30.88%)	17 / 68 (25.00%)
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	2 / 66 (3.03%)	4 / 68 (5.88%)	3 / 68 (4.41%)
occurrences (all)	2	4	3
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 66 (0.00%)	1 / 68 (1.47%)	3 / 68 (4.41%)
occurrences (all)	0	1	3
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 66 (1.52%)	1 / 68 (1.47%)	4 / 68 (5.88%)
occurrences (all)	1	2	4
Headache			
subjects affected / exposed	4 / 66 (6.06%)	4 / 68 (5.88%)	1 / 68 (1.47%)
occurrences (all)	4	4	1
Gastrointestinal disorders			
Abdominal distension			

subjects affected / exposed	1 / 66 (1.52%)	0 / 68 (0.00%)	1 / 68 (1.47%)
occurrences (all)	1	0	1
Diarrhoea			
subjects affected / exposed	2 / 66 (3.03%)	3 / 68 (4.41%)	4 / 68 (5.88%)
occurrences (all)	2	3	6
Dyspepsia			
subjects affected / exposed	0 / 66 (0.00%)	4 / 68 (5.88%)	3 / 68 (4.41%)
occurrences (all)	0	4	3
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 66 (0.00%)	1 / 68 (1.47%)	2 / 68 (2.94%)
occurrences (all)	0	1	2
Nausea			
subjects affected / exposed	2 / 66 (3.03%)	5 / 68 (7.35%)	5 / 68 (7.35%)
occurrences (all)	2	5	7
Vomiting			
subjects affected / exposed	0 / 66 (0.00%)	0 / 68 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 66 (0.00%)	1 / 68 (1.47%)	0 / 68 (0.00%)
occurrences (all)	0	1	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 66 (0.00%)	2 / 68 (2.94%)	0 / 68 (0.00%)
occurrences (all)	0	3	0
Hyperglycaemia			
subjects affected / exposed	6 / 66 (9.09%)	2 / 68 (2.94%)	1 / 68 (1.47%)
occurrences (all)	6	4	1
Hypoglycaemia			
subjects affected / exposed	0 / 66 (0.00%)	1 / 68 (1.47%)	1 / 68 (1.47%)
occurrences (all)	0	1	1

Non-serious adverse events	PF-06882961 40mg BID	PF-06882961 80mg BID	PF-06882961 120mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 71 (46.48%)	40 / 67 (59.70%)	35 / 71 (49.30%)
Investigations			

SARS-CoV-2 test positive			
subjects affected / exposed	2 / 71 (2.82%)	1 / 67 (1.49%)	1 / 71 (1.41%)
occurrences (all)	2	1	1
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 71 (1.41%)	4 / 67 (5.97%)	1 / 71 (1.41%)
occurrences (all)	1	4	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	3 / 71 (4.23%)	1 / 67 (1.49%)	5 / 71 (7.04%)
occurrences (all)	3	3	7
Headache			
subjects affected / exposed	5 / 71 (7.04%)	2 / 67 (2.99%)	7 / 71 (9.86%)
occurrences (all)	5	3	9
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	4 / 71 (5.63%)	3 / 67 (4.48%)	2 / 71 (2.82%)
occurrences (all)	5	3	3
Diarrhoea			
subjects affected / exposed	8 / 71 (11.27%)	12 / 67 (17.91%)	7 / 71 (9.86%)
occurrences (all)	10	14	7
Dyspepsia			
subjects affected / exposed	2 / 71 (2.82%)	9 / 67 (13.43%)	2 / 71 (2.82%)
occurrences (all)	2	10	2
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 71 (2.82%)	4 / 67 (5.97%)	5 / 71 (7.04%)
occurrences (all)	2	4	5
Nausea			
subjects affected / exposed	11 / 71 (15.49%)	22 / 67 (32.84%)	23 / 71 (32.39%)
occurrences (all)	13	27	32
Vomiting			
subjects affected / exposed	5 / 71 (7.04%)	11 / 67 (16.42%)	18 / 71 (25.35%)
occurrences (all)	6	17	37
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	5 / 71 (7.04%)	3 / 67 (4.48%)	1 / 71 (1.41%)
occurrences (all)	5	4	1

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 71 (2.82%)	1 / 67 (1.49%)	5 / 71 (7.04%)
occurrences (all)	2	1	5
Hyperglycaemia			
subjects affected / exposed	0 / 71 (0.00%)	4 / 67 (5.97%)	0 / 71 (0.00%)
occurrences (all)	0	4	0
Hypoglycaemia			
subjects affected / exposed	4 / 71 (5.63%)	6 / 67 (8.96%)	3 / 71 (4.23%)
occurrences (all)	6	8	3

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 May 2020	• Added exclusion of sulfasalazine (a breast cancer resistance protein [BCRP] substrate) from study as PF-06882961 has the potential to inhibit intestinal BCRP. Updated the nonclinical safety data to align with the available toxicology information (6 month toxicology study in cynomolgus monkeys). • Added the minimum time frame of monthly between safety reviews to ensure that there was ample time to prepare all data reports and ensure a timely review of safety data. The interim analysis of unblinded safety data permitted possible updates to study conduct if needed. • Lowered the cut off for blood pressure to a more conservative level to optimize blood pressure control prior to study entry.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported